EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lack of Class I Vasoreactivity Testing for Diagnosing Patients With Coronary Artery Spasm

Shozo Sueda, Yutaka Hayashi, Hiroki Ono, Hikaru Okabe, Tomoki Sakaue, Shuntaro Ikeda

Clinical Cardiology · 2024

DOI: 10.1002/clc.70004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Shozo Sueda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Minami Matsuyama Hospital, Matsuyma City, Ehime, Japan. Hauptthemen laut MEDLINE: Coronary Vasospasm, Ergonovine, Acetylcholine, Vasodilator Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vasoreactivity testing, such as intracoronary acetylcholine (ACh) or ergometrine (EM), is defined as Class I for the diagnosis of patients with vasospastic angina (VSA) according to recommendations from the Coronary Vasomotion Disorders International Study (COVADIS) group and guidelines from the Japanese Circulation Society (JCS). Hypothesis Although vasoreactivity testing is a clinically useful tool, it carries some risks and limitations in diagnosing coronary artery spasm.

Methods

Previous reports on vasoreactivity testing for diagnosing the presence of coronary spasm are summarized from the perspective of Class I.

Results

There are several problems such as reproducibility, underestimation, overestimation, and inconclusive/nonspecific results associated with daily spasm. Because provoked spasm caused by intracoronary ACh is not always similar to that caused by intracoronary EM, possibly due to different mediators, supplementary use of these vasoreactivity tests is necessary for cardiologists to diagnose VSA when a provoked spasm is not revealed by each vasoactive agent.

Conclusions

Cardiologists should understand the imperfection of these vasoreactivity tests when diagnosing patients with VSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary VasospasmErgonovineAcetylcholineVasodilator AgentsHumansReproducibility of ResultsCoronary VesselsPredictive Value of TestsVasoconstrictionVasodilation

Stichwörter der Autor:innen

acetylcholineergometrineguidelineoptimal classificationvasoreactivity testing

Substanzen

ErgonovineAcetylcholineVasodilator Agents

Autor:innen und Institutionen

  • Department of Cardiology, Minami Matsuyama Hospital, Matsuyma City, Ehime, Japan.
  • Department of Cardiology, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan.
  • Department of Cardiology, Ehime University Graduate School of Medicine, Touon-shi, Ehime, Japan.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Sueda, S., Hayashi, Y., Ono, H., Okabe, H., Sakaue, T., & Ikeda, S. (2024). Lack of Class I Vasoreactivity Testing for Diagnosing Patients With Coronary Artery Spasm. Clinical Cardiology. https://doi.org/10.1002/clc.70004

Vancouver

Sueda S, Hayashi Y, Ono H, Okabe H, Sakaue T, Ikeda S. Lack of Class I Vasoreactivity Testing for Diagnosing Patients With Coronary Artery Spasm. Clinical Cardiology. 2024. doi:10.1002/clc.70004

BibTeX
@article{Sueda2024,
  author = {Sueda, Shozo and Hayashi, Yutaka and Ono, Hiroki and Okabe, Hikaru and Sakaue, Tomoki and Ikeda, Shuntaro},
  title = {Lack of Class I Vasoreactivity Testing for Diagnosing Patients With Coronary Artery Spasm},
  journal = {Clinical Cardiology},
  year = {2024},
  doi = {10.1002/clc.70004}
}
Kostenlos starten →